Allergic rhinitis also called as hay fever, is an inflammation of the inside of the nose due to an allergic reaction to tiny particles in the air called allergens. Allergic rhinitis is also called cold-like symptoms because the symptoms resemble to cold symptoms such as sneezing, itchiness, blocked or runny nose, etc. The immune system reacts to a particular type of allergen, which causes allergic rhinitis. This reaction releases a different number of chemicals inside of mucous membrane of the nose due to which the nose becomes swollen and forms an excessive amount of mucus. Various allergens that cause allergic rhinitis include pollen, spores, house dust mites, flakes of skin, or droplets of saliva or urine from a certain animal. When allergic rhinitis is caused by pollen, it is called hay fever.
Global allergic rhinitis treatment market is estimated to be valued at US$ 14,916.9 million in 2022 and is expected to exhibit a CAGR of 4.1% during the forecast period (2022-2030).
Figure 1. Global Allergic Rhinitis Treatment Market Share (%), by Route of Administration, 2022
Global Allergic Rhinitis Treatment Market - Drivers
The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma is now available in Spain and Italy.
Moreover, increasing air pollution and climate change are expected to propel the market growth during the forecast period. For instance, in March 2020, ScienceDirect, a website which provides access to a large bibliographic database of scientific and medical publications of the Dutch publisher Elsevier, published a research paper according to which patients with allergic rhinitis exposed to pollution and climate change have significant adverse health effects. Due to induced inflammatory responses and recruitment of inflammatory cells such as cytokines and interleukins, increasing symptoms of allergic rhinitis are observed.
Allergic Rhinitis Treatment Market Report Coverage
|Base Year:||2021||Market Size in 2022:||US$ 14,916.9 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.1%||2030 Value Projection:||US$ 20,595.6 Mn|
Merck & Co., Inc., Boehringer Ingelheim International GmbH, AstraZeneca, GSK plc., Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan N.V., Aytu BioPharma, Inc., Glenmark Pharmaceuticals Ltd, Himalaya Wellness Company, Regeneron Pharmaceuticals Inc., Allergy Therapeutics, Stallergenes Greer, Bayer AG, Dr. Reddy’s Laboratories Ltd, ALK-Abelló A/S, and Revolo Biotherapeutics
|Restraints & Challenges:||
Figure 2. Global Allergic Rhinitis Treatment Market Share (%), by Region, 2022
Global Allergic Rhinitis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 641,915,931 confirmed cases infected by COVID-19 worldwide as of December 4, 2022.
COVID-19 has affected the economy in three main ways: by directly affecting the production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with the transportation of drugs and vaccines from one place to another.
Moreover, there is a significant impact of the COVID-19 pandemic on healthcare systems, and healthcare professionals (HCPs) providing care to allergic patients. As allergic diseases are highly prevalent proper care should be taken by healthcare professionals during the pandemic. For instance, in January 2022, an article was published by Wiley Online Library, according to which health care professionals (HCPs) providing care to allergic patients were affected during the pandemic in diagnostic, management, and therapeutic approaches including Allergen Immunotherapy (AIT) for respiratory, insect-venom, and food allergies. The face-to-face visit reduction was reported by 93% of health care professionals and about a quarter completely interrupted diagnostic challenges were observed and thus their was negative impact on healthcare professionals due COVID-19 pandemic.
Global Allergic Rhinitis Treatment Market: Key Developments
In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet.
In November 2021, Revolo Biotherapeutics, a biotherapeutics company, started a phase II clinical trial for IRL201104, a novel immunomodulatory peptide drug indicated for seasonal allergic rhinitis. The study is expected to be completed in February 2023.
Global Allergic Rhinitis Treatment Market: Restraint
The major factors that are expected to hinder growth of the global allergic rhinitis treatment market include the termination of the clinical trial study. For instance, in November 2022, a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.
Global Allergic Rhinitis Treatment Market- Key Players
Major players operating in the global allergic rhinitis treatment market include Merck & Co., Inc., Boehringer Ingelheim International GmbH, AstraZeneca, GSK plc., Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan N.V., Aytu BioPharma, Inc., Glenmark Pharmaceuticals Ltd, Himalaya Wellness Company, Regeneron Pharmaceuticals Inc., Allergy Therapeutics, Stallergenes Greer, Bayer AG, Dr. Reddy’s Laboratories Ltd, ALK-Abelló A/S and Revolo Biotherapeutics, among other prominent players
Frequently Asked Questions